TY - JOUR 
A1 - Berenguer, Juan
AU - Von Wichmann, Miguel A.
AU - Quereda, Carmen
AU - Miralles, Pilar
AU - Mallolas, Josep
AU - López-Aldeguer, José
AU - Álvarez-Pellicer, Julio
AU - Miguel, Julio de
AU - Crespo, Manel
AU - Guardiola, Josep M.
AU - Téllez, María J.
AU - Galindo, María J.
AU - Arponen, Sari
AU - Barquilla Díaz, Elena
AU - Bellón Cano, José María
AU - González-García, Juan
AU - Cosín, J.
AU - López, J. C.
AU - Padilla, B.
AU - Conde, M. S.
AU - Gutiérrez, I.
AU - Ramírez, Manuel
AU - Carretero, S.
AU - Aldamiz-Echevarría, T.
AU - Tejerina, F.
AU - Rodríguez, E.
AU - Arribas, José R.
AU - Bernardino, José Ignacio
AU - Pascual-Pareja, J. F.
AU - Zamora, F. X.
AU - Peña, J. M.
AU - Arnalich, Francisco
AU - Bustinduy, M. J.
AU - Iribarren, José Antonio
AU - Rodríguez-Arrondo, F.
AU - Blanes, M.
AU - Cuellar, S.
AU - Lacruz, J.
AU - Montero, M.
AU - Salavert, M.
AU - Callau, P.
AU - Miró, J. M.
AU - Gatell, J. M.
AU - Ferrer, A.
AU - Van den Eynde, E.
AU - Pérez, M.
AU - Ribera, E.
AU - Vergas, J.
AU - Casado Osorio, José L.
AU - Dronda, Fernando
AU - Moreno, Ana
AU - Pérez Elías, María Jesús
AU - Sanfrutos, M. A.
AU - Moreno, S.
AU - Jou, A.
AU - Tural, Cristina
AU - Arranz, J. L.
AU - Casas, E.
AU - Schroeder, S.
AU - Sanz, J.
AU - Condés Moreno, Emilia
AU - Barros, Carlos
AU - Santos, I.
AU - Hernando Jeréz, María Asunción
AU - Rodríguez, V.
AU - Rubio, Rafael
AU - Pulido, Federico
AU - Domingo Pedrol, Pere
AU - Ortiz, L.
AU - Ortega, Eduardo
AU - Torres, R.
AU - Cervero, M.
AU - Jusdado, J. J.
AU - Montes-Ramírez, M. L.
AU - Pérez, G.
AU - Gaspar, G.
AU - Mahillo, B.
AU - Moyano, B.
AU - Cotarelo, M.
AU - Aznar, E.
AU - Esteban, Herminia
T1 - Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus
Y1 - 2011
UR - http://hdl.handle.net/11268/279
AB - The effects of antiretroviral drugs on the response to pegylated interferon plus ribavirin remain uncertain. We evaluated whether antiretroviral drugs affected the response to pegylated interferon plus ribavirin in patients co-infected with HIV and hepatitis C virus (HCV). We conducted a retrospective analysis of two cohorts of HIV/HCV-co-infected patients treated with pegylated interferon plus ribavirin between 2001 and 2007 in Spain. The outcome measure was sustained virological response (SVR). Logistic regression models were used to test possible associations between non-response and pre-treatment characteristics, including accompanying antiretroviral drugs. The study sample comprised 1701 patients: 63% were infected with HCV genotype (G) 1 or 4 and 88% were taking highly active antiretroviral therapy (HAART). Factors independently associated with increased odds of SVR were G2 or 3, HVC RNA <500,000 IU/mL and CDC clinical category A or B. When we adjusted for these prognostic factors and dose of ribavirin/kg, the adjusted odds ratio (AOR) of SVR for patients without HAART was 1.31 [95% confidence interval (CI) 0.91-1.88; P = 0.144]. Taking the backbone of tenofovir and lamivudine/emtricitabine as a reference, we found that, with the exception of regimens including zidovudine, the effect of other nucleoside reverse transcriptase inhibitor backbones had little effect on SVR. The AOR of SVR for zidovudine and lamivudine was 0.65 (95% CI 0.46-0.93, P = 0.017). We carried out several sensitivity analyses, the results of which were consistent with the findings of the primary analysis. In conclusion, our results suggest that, with the exception of regimens including zidovudine, accompanying antiretroviral drugs have little effect on the virological response to pegylated interferon plus ribavirin in HIV/HCV-co-infected patients.
KW - Sida
LA - eng
ER -